MedTrace Logo

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

NCT01300156 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-02-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma (HL).

Conditions

  • Hodgkin's Lymphoma

Interventions

DRUG

Oxaliplatin-based chemotherapy (ESHAOx)

* Etoposide 40 mg/m2, D1-4 * Methylprednisolone 500mg, D1-5 * Cytarabine 2 g/m2, D5 * Oxaliplatin 130 mg/m2, D1

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Hyeon Seok Eom, MD, PhD · National Cancer Center, Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01300156 on ClinicalTrials.gov